Related Experiment Video

Updated: Aug 11, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Folate-mediated targeting of T cells to tumors

Edward J Roy1, Ute Gawlick, Brent A Orr

  • 1Neuroscience Program, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

Advanced Drug Delivery Reviews
|April 20, 2004
PubMed

Insights

This review explores using folate receptors (FRs) to target T cells for cancer therapy. Strategies include bispecific antibodies and vaccines to enhance T cell-mediated tumor destruction.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • T cells can specifically recognize and destroy tumor cells.
  • Various strategies are being developed to leverage this for clinical cancer treatment.
  • High-affinity folate receptors (FRs) are present on tumor cells.

Purpose of the Study:

  • To review strategies targeting cancer using T cells directed by folate receptors.
  • To explore the use of bispecific antibodies and vaccines involving FRs.
  • To discuss the potential of FRs on antigen-presenting cells for vaccine design.

Main Methods:

  • Review of studies utilizing bispecific antibodies (anti-T cell/anti-tumor cell).
  • Exploration of vaccines designed to induce tumor-reactive T cells.
  • Discussion of adoptive T cell transfer strategies.
  • Focus on folate receptor-targeted approaches.

Main Results:

  • Bispecific antibody conjugates of folate and T cell receptor (TCR) antibodies can generate tumor-reactive T cell responses.
  • Folate/antibody conjugates targeting CD28 may enhance T cell recognition of tumor antigens.
  • High-affinity FRs on antigen-presenting cells (APCs) offer potential for tumor-antigen-specific vaccines.

Conclusions:

  • Folate receptors represent a promising target for enhancing T cell-mediated cancer immunotherapy.
  • Bispecific antibodies and novel vaccine designs utilizing FRs show potential for clinical application.
  • Targeting FRs on APCs could lead to new vaccine strategies against cancer.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...